Literature DB >> 28509219

Atypical hemolytic uremic syndrome with MCP mutations preceded by respiratory infection.

Keiko Yasuda1,2, Koichi Sasaki3, Masaya Yamato3, Hiromi Rakugi4, Yoshitaka Isaka4, Terumasa Hayashi5, Rossella Piras6, Elena Bresin6.   

Abstract

A 14-year-old boy was referred to our hospital with general fatigue and sore throat. A chest X-ray and computed tomography revealed diffuse bilateral bronchitis. A laboratory examination showed anemia, thrombocytopenia, and renal insufficiency. He had a past medical history of hemolytic uremic syndrome (HUS) without diarrhea at the age of 3; moreover, his elder brother suffered from HUS at the age of 12. These findings indicated that the patient had a familial relapsing form of HUS (atypical HUS). Therefore, he was immediately treated with plasma exchange (PE), as suggested by guidelines, obtaining complete remission. Fifteen months later, he suffered another relapse of atypical HUS preceded by respiratory infection and was cured again with PE. His ADAMTS-13 activity was normal and its inhibitory antibody was undetectable. Two different mutations were found in the gene encoding membrane cofactor protein (MCP). Respiratory infections preceded all three episodes of HUS, but we could not detect the pathogenic agent. Although the long-term outcomes of patients with atypical HUS who have mutations in the MCP gene appear favorable, recurrences are nevertheless frequent. Few reports have described Japanese patients with atypical HUS and complement regulatory abnormalities. This is the first report of a Japanese patient with atypical HUS and mutations in the MCP gene.

Entities:  

Keywords:  Atypical hemolytic uremic syndrome; Membrane cofactor protein; Mutations

Year:  2012        PMID: 28509219      PMCID: PMC5413724          DOI: 10.1007/s13730-012-0034-1

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  16 in total

1.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors:  Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

2.  Eculizumab for atypical hemolytic-uremic syndrome.

Authors:  Jens Nürnberger; Thomas Philipp; Oliver Witzke; Anabelle Opazo Saez; Udo Vester; Hideo Andreas Baba; Andreas Kribben; Lothar Bernd Zimmerhackl; Andreas R Janecke; Mato Nagel; Michael Kirschfink
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

3.  Eculizumab for congenital atypical hemolytic-uremic syndrome.

Authors:  Ralph A Gruppo; Russell P Rother
Journal:  N Engl J Med       Date:  2009-01-29       Impact factor: 91.245

Review 4.  Atypical hemolytic-uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

5.  Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome.

Authors:  Gema Ariceta; Nesrin Besbas; Sally Johnson; Diana Karpman; Daniel Landau; Christoph Licht; Chantal Loirat; Carmine Pecoraro; C Mark Taylor; Nicole Van de Kar; Johan Vandewalle; Lothar B Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-09-18       Impact factor: 3.714

Review 6.  The pathogenesis and treatment of hemolytic uremic syndrome.

Authors:  B S Kaplan; K E Meyers; S L Schulman
Journal:  J Am Soc Nephrol       Date:  1998-06       Impact factor: 10.121

7.  Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.

Authors:  Marina Noris; Jessica Caprioli; Elena Bresin; Chiara Mossali; Gaia Pianetti; Sara Gamba; Erica Daina; Chiara Fenili; Federica Castelletti; Annalisa Sorosina; Rossella Piras; Roberta Donadelli; Ramona Maranta; Irene van der Meer; Edward M Conway; Peter F Zipfel; Timothy H Goodship; Giuseppe Remuzzi
Journal:  Clin J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 8.237

Review 8.  A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders.

Authors:  N Besbas; D Karpman; D Landau; C Loirat; W Proesmans; G Remuzzi; G Rizzoni; C M Taylor; N Van de Kar; L B Zimmerhackl
Journal:  Kidney Int       Date:  2006-06-14       Impact factor: 10.612

Review 9.  Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.

Authors:  P Ruggenenti; M Noris; G Remuzzi
Journal:  Kidney Int       Date:  2001-09       Impact factor: 10.612

10.  Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome.

Authors:  Anne-Laure Sellier-Leclerc; Veronique Fremeaux-Bacchi; Marie-Agnès Dragon-Durey; Marie-Alice Macher; Patrick Niaudet; Geneviève Guest; Bernard Boudailliez; François Bouissou; Georges Deschenes; Sophie Gie; Michel Tsimaratos; Michel Fischbach; Denis Morin; Hubert Nivet; Corinne Alberti; Chantal Loirat
Journal:  J Am Soc Nephrol       Date:  2007-06-28       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.